Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|July 2, 2020
- Pharmaceutical Technology-07-02-2020
- Volume 44
- Issue 7
Double Planetary Mixer
The Double Planetary Mixer from Ross is scalable through 1000-gallon production models and is offered in a sanitary turnkey configuration that features a stainless-steel workbench for the mixer and discharge system.
The Double Planetary Mixer from Ross is scalable through 1000-gallon production models and is offered in a sanitary turnkey configuration that features a stainless-steel workbench for the mixer and discharge system. The sanitary four-gallon Double Planetary Mixer & Discharge System Model DPM/DS-4S (pictured) includes interior and exterior stainless-steel, and type 316 surfaces with an electropolished, 150-grit finish. The mixer’s jacketed mixing vessel and high viscosity blades are equipped to produce thick gels, pastes, putties, and other semi-solids under specific temperatures, and its sealed gearbox and stirrer shafts help ensure complete cleanability and eliminate cross-contamination between batches.
Articles in this issue
over 6 years ago
Performing Remote Audits During the Pandemicover 6 years ago
Demand for Custom Dosage Forms Fuels Innovationover 6 years ago
Learning Regulatory Lessons in Times of a Crisisover 6 years ago
Business on Hold? EMA’s Full Recovery in Questionover 6 years ago
Taking a Controlled Approachover 6 years ago
Unprecedented Times in Vaccinesover 6 years ago
No Business, Like Brexit Businessover 6 years ago
Innovating Continuous Twin-Screw Granulation with Foam DeliveryRelated to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Germany’s Medical Biotechnology Sector is Flourishing
5